Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743575 | 0.83 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL11979484 | 0.77 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL20743495 | 0.75 | MAPK1 (0.32) | — | |
| SCHEMBL6113452 | 0.75 | — | — | |
| SCHEMBL2103021 | 0.75 | CYP2C19 (0.39) | CYP2C19 | |
| SCHEMBL22345263 | 0.73 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL822934 | 0.72 | USP2 (0.46) | CYP2C19 | |
| SCHEMBL14790645 | 0.72 | USP2 (0.35) | — | |
| SCHEMBL5170438 | 0.72 | TP53 (0.33) | — | |
| SCHEMBL20743648 | 0.72 | POLB (0.39) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803826-B2 | Imidazolidine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-25 | — | — | US | disclosed |
| US-7271188-B2 | Imidazolidine derivatives | CHUGAI SEIKAYU KABUSHIKI KAISHA (JP) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249697-A1 | Novel Imidazolidine Derivatives | CYP3A4, CYP4B1, OPRD1 | CYP2C19 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.